This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%
Merck (MRK) cut into Keytruda alone by showing intismeran autogene in a Phase 3 trial reduced the risk of cancer recurrence or death and improved distant metastasis-free survival versus Keytruda, a development that pushed shares up 11% in August.
Sep 16, 2026 ·
Yahoo Finance


















